Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NestmedicWAR:NST -0.52%38 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates WAR:NST with a GF Score™ of 38/100 and a GF Value™ of zł0.41 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 702 Medical Devices & Instruments companies, Nestmedic ranks better than 74.5% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Nestmedic's Debt-to-Equity or its related term are showing as below:
WAR:NST'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03 Med: 0.14 Max: 7.76
Current: 0.07
During the past 11 years, the highest Debt-to-Equity Ratio of Nestmedic was 7.76. The lowest was -0.03. And the median was 0.14.
WAR:NST's Debt-to-Equity is ranked better than 74.5% of 702
companies
in the Medical Devices & Instruments industry
Industry Median: 0.22
vs WAR:NST: 0.07
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Nestmedic Debt-to-Equity Related Terms
Nestmedic Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Nestmedic's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:NST vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Nestmedic's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nestmedic Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nestmedic's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Nestmedic's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nestmedic (WAR:NST) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nestmedic and its competitors. According to the industry distribution chart, Nestmedic ranks #179 out of 702 companies in the Medical Devices & Instruments industry, placing it in the top 25.5%.
Is Nestmedic's Debt-to-Equity too high?
Nestmedic's current Debt-to-Equity is 0.00. Based on the distribution chart, Nestmedic ranks #179 out of 702 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nestmedic has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nestmedic's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nestmedic ranks #179 out of 702 companies for Debt-to-Equity. This puts Nestmedic in the upper half of its industry. The industry median Debt-to-Equity is 0.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.22, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nestmedic and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nestmedic's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nestmedic stock overvalued right now?
Based on GuruFocus' analysis, Nestmedic (WAR:NST) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.41, compared to a current price of zł0.76 — trading 86.3% above its estimated fair value. The current Debt-to-Equity is 0.00. Nestmedic's overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Nestmedic (WAR:NST), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nestmedic (WAR:NST) Overvalued in 2026?
Based on GuruFocus' analysis, Nestmedic stock appears to be overvalued.
The current stock price of zł0.76 is trading 86.3% above its estimated GF Value™ of zł0.41.
GuruFocus considers Nestmedic to be Significantly Overvalued.
Key valuation signals for WAR:NST:
Debt-to-Equity: 0.00
GF Value™: zł0.41 vs. price of zł0.76 (86.3% above fair value)
No single metric tells the full story. See the WAR:NST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nestmedic SA is a manufacturer of mobile telemedicine solution Pregnabit for remote fetal well-being - cardiotocographic (KTG). Pregnabit consists of a medical device (teleKTG) allowing to reliably and safely retrieve data using certified medical probes.
38GF Score
Get the complete analysis for WAR:NST
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:NST has been successfully added to your 
